HPS (women subgroup) 2002

1 Treatments

Studied treatment  Simvastatin 40 mg

Control treatment  placebo

Concomittant treatments  -

initial women proportion in the trial  1816/5963 (30%)

2 Patients

Patients  UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes - subgroup of women without CHD

Inclusion criteria  -

Exclusion criteria  -

prior CHD (%)  0%

baseline CT  224 mg/dL

baseline LDL  131 mg/dL

3 Methods

Blinding  double blind

Design  Parallel groups

Centers  1

Geographical area  UK

Sizes  914/902

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cv events</td>
<td>-/914</td>
<td>-/902</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>All cause mortality</td>
<td>-/914</td>
<td>-/902</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CHD events</td>
<td>130/914</td>
<td>168/902</td>
<td>0,76</td>
<td>[0,59; 0,98]</td>
</tr>
<tr>
<td>cancer</td>
<td>-/914</td>
<td>-/902</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References